| Stage | BLMN | % of rev | MCD | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.0B | 100.00% | $7.1B | 100.00% | MCD ×6.99 |
| Gross profit | $397M | 39.06% | $4.3B | 60.30% | MCD +21.2pp |
| Operating income | $38M | 3.77% | $3.3B | 47.02% | MCD +43.3pp |
| Pre-tax income | $27M | 2.67% | $2.9B | 41.36% | MCD +38.7pp |
| Net income | $33M | 3.21% | $2.4B | 33.27% | MCD +30.1pp |
| Stage | BLMN | MCD | Gap · A − B |
|---|---|---|---|
| Revenue | $1.0B100.00% | $7.1B100.00% | MCD ×6.99 |
| Gross profit | 39.06%$397M | 60.30%$4.3B | MCD +21.2pp |
| Operating income | 3.77%$38M | 47.02%$3.3B | MCD +43.3pp |
| Pre-tax income | 2.67%$27M | 41.36%$2.9B | MCD +38.7pp |
| Net income |
| 3.21%$33M |
| 33.27%$2.4B |
| MCD +30.1pp |
None
No disclosed counterparties: BLMN.